Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|MAP2K1 K57_G61del||lymphatic system cancer||predicted - sensitive||MEK inhibitor (Pan) MEK1 Inhibitor||Trametinib||Case Reports/Case Series||Actionable||In a clinical case study, a pediatric patient with Langerhans cell histiocytosis harboring MAP2K1 K57_G61del treated with Mekinist (trametinib) achieved a rapid complete response and had no active disease over 22 months of treatment (PMID: 32991018).||32991018|
|MAP2K1 K57_G61del||Advanced Solid Tumor||sensitive||MEK inhibitor (Pan) MEK1 Inhibitor||Trametinib||Preclinical - Cell culture||Actionable||In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 K57_G61del in culture (PMID: 36442478).||36442478|